替诺福韦与恩替卡韦对初治慢性乙型肝炎患者肝细胞癌及死亡风险比较:韩国大规模倾向评分分析
该研究在韩国天主教大学肝脏中心筛选了2007年2月至2018年1月间连续接受替诺福韦(TDF)或恩替卡韦(ETV)治疗的7015例初治慢性乙型肝炎(CHB)患者,最终分析3022例。采用倾向评分匹配(PSM)和逆概率治疗加权法比较两组5年内肝细胞癌(HCC)及全因死亡或肝移植(LT)风险,结果显示TDF与ETV在HCC发生率和死亡/LT风险上均无显著差异。
要点
- 在初治CHB患者中,TDF与ETV对5年内HCC风险的影响无显著差异。
- 两药对5年内全因死亡或肝移植风险的影响亦无显著差异。
- 亚组分析显示,在慢性肝炎和肝硬化患者中结果一致。
核心结论
- 在初治慢性乙型肝炎患者中,替诺福韦与恩替卡韦在中期(5年)肝细胞癌风险及死亡或肝移植风险方面无差异。
研究设计与样本
- 研究为大规模倾向评分分析,筛选2007年2月至2018年1月韩国天主教大学肝脏中心连续接受TDF或ETV治疗的7015例初治CHB患者,最终分析3022例。
- 研究终点为抗病毒治疗开始后5年内的HCC发生和全因死亡或肝移植(LT),采用倾向评分匹配(PSM)和逆概率治疗加权(IPTW)方法。
主要发现
- 整个队列中,TDF与ETV的HCC发生率无差异(HR 1.030;95% CI 0.703至1.509,PSM模型,p=0.880)。
- 在慢性肝炎和肝硬化亚组中,TDF与ETV的HCC发生率亦无差异。
- 整个队列中,TDF与ETV的全因死亡或LT发生率无差异(HR 1.090;95% CI 0.622至1.911,PSM模型,p=0.763)。
- 在慢性肝炎和肝硬化患者中,TDF与ETV的全因死亡或LT发生率亦无差异。
临床怎么用
- 对于初治CHB患者,选择TDF或ETV时无需优先考虑两者对中期HCC及死亡/LT风险的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcomes has not been clarified thus far. Therefore, we aimed to compare TDF and ETV on the risk of HCC and mortality. DESIGN: A total of 7015 consecutive patients with CHB who were treated with TDF or ETV between February 2007 and January 2018 at the liver units of the Catholic University of Korea were screened for study eligibility and 3022 patients were finally analysed. Study end points were HCC and all-cause mortality or liver transplantation (LT) within 5 years after the initiation of antiviral therapy. Propensity score matching (PSM) and inverse probability of treatment weighting methods were used. RESULTS: No difference was observed between TDF and ETV in the incidence rates of HCC in the entire cohort (HR 1.030; 95% CI 0.703 to 1.509, PSM model, p=0.880) and subgroups of patients with chronic hepatitis and cirrhosis. Also, no difference was observed between TDF and ETV in the incidence rates of all-cause mortality or LT in the entire cohort (HR 1.090; 95% CI 0.622 to 1.911, PSM model, p=0.763), and patients with chronic hepatitis and cirrhosis. CONCLUSION: This study has demonstrated the clinical outcomes in patients with CHB who received TDF or ETV treatment. There was no difference in the intermediate-term risk of HCC and mortality or LT between the two drugs.
引用
- Lee SW, Kwon JH, Lee HL, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2019. PMID: 31672838. doi:10.1136/gutjnl-2019-318947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。